Institution
Jagiellonian University
Education•Krakow, Poland•
About: Jagiellonian University is a education organization based out in Krakow, Poland. It is known for research contribution in the topics: Population & Catalysis. The organization has 17438 authors who have published 44092 publications receiving 862633 citations. The organization is also known as: Academia Cracoviensis & Akademia Krakowska.
Topics: Population, Catalysis, Large Hadron Collider, Galaxy, European union
Papers published on a yearly basis
Papers
More filters
••
Memorial Sloan Kettering Cancer Center1, Hofstra University2, Harvard University3, University of Barcelona4, Vita-Salute San Raffaele University5, University of Debrecen6, Jagiellonian University7, Princess Alexandra Hospital8, Lille University of Science and Technology9, Medical University of Łódź10, Willamette University11, North Shore Hospital12, Charles University in Prague13, University of Ulm14, St James's University Hospital15
TL;DR: Ielalisib plus BR is superior to BR alone, improving PFS and OS, and represents an important new treatment option for patients with R/R CLL.
Abstract: Summary Background Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population. Methods For this international, multicentre, double-blind, placebo-controlled trial, adult patients (≥18 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measurable lymphadenopathy by CT or MRI and disease progression within 36 months since their last previous therapy were enrolled. Patients were randomly assigned (1:1) by a central interactive web response system to receive bendamustine plus rituximab for a maximum of six cycles (bendamustine: 70 mg/m 2 intravenously on days 1 and 2 for six 28-day cycles; rituximab: 375 mg/m 2 on day 1 of cycle 1, and 500 mg/m 2 on day 1 of cycles 2–6) in addition to either twice-daily oral idelalisib (150 mg) or placebo until disease progression or intolerable study drug-related toxicity. Randomisation was stratified by high-risk features ( IGHV , del[17p], or TP53 mutation) and refractory versus relapsed disease. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat population. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01569295. Findings Between June 26, 2012, and Aug 21, 2014, 416 patients were enrolled and randomly assigned to the idelalisib (n=207) and placebo (n=209) groups. At a median follow-up of 14 months (IQR 7–18), median progression-free survival was 20·8 months (95% CI 16·6–26·4) in the idelalisib group and 11·1 months (8·9–11·1) in the placebo group (hazard ratio [HR] 0·33, 95% CI 0·25–0·44; p vs 52 [25%] of 209). Serious adverse events, including febrile neutropenia, pneumonia, and pyrexia, were more common in the idelalisib group (140 [68%] of 207 patients) than in the placebo group (92 [44%] of 209). Treatment-emergent adverse events leading to death occurred in 23 (11%) patients in the idelalisib group and 15 (7%) in the placebo group, including six deaths from infections in the idelalisib group and three from infections in the placebo group. Interpretation Idelalisib in combination with bendamustine plus rituximab improved progression-free survival compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukaemia. However, careful attention needs to be paid to management of serious adverse events and infections associated with this regimen during treatment selection. Funding Gilead Sciences Inc.
191 citations
••
TL;DR: In this paper, an upper bound of 90% C.L. on the ratio between the U coupling constant and the fine structure constant of alpha/alpha < 1.7 fb(-1) was established.
190 citations
••
TL;DR: U samic nornicy rudej Clethrionomys glareolus określano zuzycie pokarmu i energie strawioną (asymilacje) w ciŅgu calego okresu ciązy i laktacji (18 + 18 dni).
Abstract: U samic nornicy rudej Clethrionomys glareolus (Schreber, 1780) określano zuzycie pokarmu i energie strawioną (asymilacje) w ciągu calego okresu ciązy i laktacji (18 + 18 dni).
190 citations
••
TL;DR: The results indicate that the clinically used photosensitizer VP is a potent inhibitor of cell growth in retinoblastoma cells, disrupting YAP-TEAD signaling and pluripotential marker OCT4.
189 citations
••
TL;DR: In this paper, the changes in the structure of wool fiber keratin were studied by means of Fourier-transform Infrared and Raman Spectroscopy, and the attempt of interruption of this process in the presence of siliceous compounds was made.
189 citations
Authors
Showing all 17729 results
Name | H-index | Papers | Citations |
---|---|---|---|
Roxana Mehran | 141 | 1378 | 99398 |
Brad Abbott | 137 | 1566 | 98604 |
M. Morii | 134 | 1664 | 102074 |
M. Franklin | 134 | 1581 | 95304 |
John Huth | 131 | 1087 | 85341 |
Wladyslaw Dabrowski | 129 | 990 | 79728 |
Rostislav Konoplich | 128 | 811 | 73790 |
Michel Vetterli | 128 | 901 | 76064 |
Francois Corriveau | 128 | 1022 | 75729 |
Christoph Falk Anders | 126 | 734 | 68828 |
Tomasz Bulik | 121 | 698 | 86211 |
Elzbieta Richter-Was | 118 | 793 | 69127 |
S. H. Robertson | 116 | 1311 | 58582 |
S. J. Chen | 116 | 1559 | 62804 |
David M. Stern | 107 | 271 | 47461 |